A network to understand and track people at risk for psychosis
ProNET: Psychosis-Risk Outcomes Network
This project follows people with early signs of possible psychosis and healthy volunteers over two years using brain scans, EEG, blood and genetic tests, speech and thinking tests, surveys, and smartphone data to find patterns linked to different outcomes.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11382287 on NIH RePORTER |
What this research studies
If you join, you would complete detailed visits at one of the ProNET sites that include MRI and EEG brain measures, blood and genetic samples, cognitive and symptom testing, recorded speech, and passive smartphone sensing; many of these measures are repeated at two timepoints and clinical outcomes are tracked at eight visits over 24 months. The network will enroll about 1,040 people who meet clinical high-risk (CHR) criteria and about 260 healthy volunteers across 26 international sites. Researchers will use the combined clinical, biological, and digital data to identify groups and markers that relate to whether symptoms improve, stay the same, or progress to psychosis. Some exploratory analyses will test novel EEG signals and real-time smartphone-based symptom reports.
Who could benefit from this research
Good fit: Ideal participants are people with early or mild symptoms that suggest higher risk for psychosis (clinical high-risk/attenuated symptoms) who can attend repeated in-person visits and provide samples and smartphone data.
Not a fit: People without CHR signs, those already in a full psychotic episode requiring urgent treatment, or those seeking an immediate therapeutic drug are unlikely to receive direct benefit from this observational network.
Why it matters
Potential benefit: If successful, the project could help clinicians identify who is most likely to develop psychosis and tailor earlier, more personalized care.
How similar studies have performed: Previous longitudinal CHR studies have found some risk markers but results have been inconsistent, and this larger, multimodal effort aims to improve prediction accuracy.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Woods, Scott W — Yale University
- Study coordinator: Woods, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.